Liu, Xuan
Ge, Zhongqi
Yang, Fei http://orcid.org/0000-0001-8762-8033
Contreras, Alejandro
Lee, Sanghoon
White, Jason B. http://orcid.org/0000-0001-7140-545X
Lu, Yiling
Labrie, Marilyne http://orcid.org/0000-0003-3957-5533
Arun, Banu K.
Moulder, Stacy L.
Mills, Gordon B. http://orcid.org/0000-0002-0144-9614
Piwnica-Worms, Helen http://orcid.org/0000-0003-4210-6738
Litton, Jennifer K.
Chang, Jeffrey T. http://orcid.org/0000-0002-4578-5636
Article History
Received: 9 April 2021
Accepted: 12 April 2022
First Online: 10 May 2022
Competing interests
: G.B.M. is a board member or consultant for AstraZeneca, Chrysallis Biotechnology, GlaxoSmithKline, ImmunoMET, Ionis, Eli Lilly, PDX Pharmaceuticals, Signalchem Life Science, Symphogen, Tarveda, Turbine, Zentalis Pharmaceuticals; a shareholder of Catena Pharmaceuticals, ImmunoMet, SignalChem, and Tarveda; and has licensed technology to Myriad Genetics and Nanostring. J.K.L. has research support from Novartis, Medivation/Pfizer, Genentech, GlaxoSmithKline, EMD-Serono, Astra-Zeneca, Medimmune, and Zenith; is a board member or consultant for Astra-Zeneca, Ayala, and Pfizer (all uncompensated); and is on the speaker’s bureau for MedLearning, Physician’s Education Resource, Prime Oncology, Medscape, Clinical Care Options, and Medpage. Other authors declare no competing interests.